Who is sponsoring NCT03357289?

NCT03357289 is sponsored by Fuda Cancer Hospital, Guangzhou.

What drugs are being tested in NCT03357289?

Interventions in NCT03357289: Mix vaccine.

Is NCT03357289 still recruiting?

NCT03357289 is currently completed. Last updated 12 September 2019.

Last reviewed 2019-09-12 · How we verify

NCT03357289

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mix Vaccine for Metastatic Kidney Cancer

Completed Phase 1, PHASE2 Last updated 12 September 2019

What this trial tests

Phase 1, PHASE2 trial testing Mix vaccine in Metastasis From Malignant Tumor of Kidney (Disorder) in 30 participants. Completed in 30 August 2019.

Timeline

30 November 2017

Primary endpoint
30 November 2018

30 August 2019

Quick facts

Lead sponsor	Fuda Cancer Hospital, Guangzhou
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	30 November 2017
Primary completion	30 November 2018
Estimated completion	30 August 2019
Sites	1 location across China

Drugs / interventions tested

Mix vaccine — full drug profile →

Conditions studied

Metastasis From Malignant Tumor of Kidney (Disorder) — all drugs for Metastasis From Malignant Tumor of Kidney (Disorder) →
Reaction - Mixed Vaccine — all drugs for Reaction - Mixed Vaccine →

Sponsor

Fuda Cancer Hospital, Guangzhou

Who can join

Adults 40 to 70, any sex, with Metastasis From Malignant Tumor of Kidney (Disorder) or Reaction - Mixed Vaccine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is the safety and efficacy of mix vaccine to small metastases of kidney cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Biomaterials nanoplatform-based tumor vaccines for immunotherapy.
Li Z, Zhang H, Gong Q, Luo K. · · 2025 · cited 10× · PMID 40678264 · DOI 10.1016/j.bioactmat.2025.06.038

Verify or expand the search:

Other trials of Mix vaccine

Trials testing the same drug.

NCT03357315 — Mix Vaccine for Metastatic Sarcoma Patients · Phase 1, PHASE2 · completed
NCT03357276 — Mix Vaccine for Metastatic Colorectal Cancer · Phase 1, PHASE2 · completed

Other Fuda Cancer Hospital, Guangzhou trials

Trials by the same sponsor.

NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03357289 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
Last refreshed: 12 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03357289.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing